Association between initial opioid use and response to a brief interdisciplinary treatment program in fibromyalgia.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
entrez:
5
1
2019
pubmed:
5
1
2019
medline:
29
1
2019
Statut:
ppublish
Résumé
To evaluate the association between opioid use and treatment outcome (symptom severity, quality of life [QOL]) after a brief interdisciplinary fibromyalgia treatment program (FTP). Subjects (n = 971) with fibromyalgia participated in the FTP. They filled out the Fibromyalgia Impact Questionnaire (FIQ) and the Short Form-36 Health Status Questionnaire (SF-36) at baseline and 6 to 12 months after the FTP. Post-treatment changes in FIQ and SF-36 scores were compared after stratifying the participants into opioid user and non-opioid user groups. A total of 236 patients (24.3%) were opioid users. Compared with non-opioid users, the opioid users had worse symptom severity measured using FIQ total score (p < .001) and all subscales at baseline and post treatment, as well as worse QOL measured using all SF-36 subscales and physical and mental components. Comparison of least-square means of mean change of QOL between opioid users and non-opioid users after analysis of covariance adjusted patient characteristics and baseline scores showed that the FIQ subscale scores of physical impairment (p < .05), job ability (p < .05), and fatigue (p < .05) were significantly less improved in the opioid users compared with the non-opioid users. Moreover, the SF-36 subscale score of general health perception (p < .05) was significantly less improved in the opioid users compared with non-opioid users. However, post-treatment changes in mean scores for QOL subscale generally did not significantly differ in both groups. Opioid use did not affect response to the FTP, as measured using the FIQ total score or SF-36 physical and mental component summary scores. Furthermore, the opioid user group showed less improvement in the FIQ subscale scores of physical impairment, job ability, and fatigue and in the SF-36 subscale scores of general health perception.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the association between opioid use and treatment outcome (symptom severity, quality of life [QOL]) after a brief interdisciplinary fibromyalgia treatment program (FTP).
METHOD
METHODS
Subjects (n = 971) with fibromyalgia participated in the FTP. They filled out the Fibromyalgia Impact Questionnaire (FIQ) and the Short Form-36 Health Status Questionnaire (SF-36) at baseline and 6 to 12 months after the FTP. Post-treatment changes in FIQ and SF-36 scores were compared after stratifying the participants into opioid user and non-opioid user groups.
RESULTS
RESULTS
A total of 236 patients (24.3%) were opioid users. Compared with non-opioid users, the opioid users had worse symptom severity measured using FIQ total score (p < .001) and all subscales at baseline and post treatment, as well as worse QOL measured using all SF-36 subscales and physical and mental components. Comparison of least-square means of mean change of QOL between opioid users and non-opioid users after analysis of covariance adjusted patient characteristics and baseline scores showed that the FIQ subscale scores of physical impairment (p < .05), job ability (p < .05), and fatigue (p < .05) were significantly less improved in the opioid users compared with the non-opioid users. Moreover, the SF-36 subscale score of general health perception (p < .05) was significantly less improved in the opioid users compared with non-opioid users. However, post-treatment changes in mean scores for QOL subscale generally did not significantly differ in both groups.
CONCLUSIONS
CONCLUSIONS
Opioid use did not affect response to the FTP, as measured using the FIQ total score or SF-36 physical and mental component summary scores. Furthermore, the opioid user group showed less improvement in the FIQ subscale scores of physical impairment, job ability, and fatigue and in the SF-36 subscale scores of general health perception.
Identifiants
pubmed: 30608417
doi: 10.1097/MD.0000000000013913
pii: 00005792-201901040-00037
pmc: PMC6344169
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13913Références
Pain Physician. 2011 Mar-Apr;14(2):E217-45
pubmed: 21412381
Pain Physician. 2011 Mar-Apr;14(2):145-61
pubmed: 21412369
Int J Rheum Dis. 2011 Feb;14(1):6-11
pubmed: 21303476
Arthritis Rheum. 1990 Feb;33(2):160-72
pubmed: 2306288
J Clin Rheumatol. 2000 Oct;6(5):250-7
pubmed: 19078481
J Neurosci. 2007 Sep 12;27(37):10000-6
pubmed: 17855614
Ann Rheum Dis. 2008 Apr;67(4):536-41
pubmed: 17644548
BMC Musculoskelet Disord. 2004 Dec 09;5:48
pubmed: 15588296
Arthritis Care Res (Hoboken). 2010 May;62(5):600-10
pubmed: 20461783
Am J Phys Med Rehabil. 2010 Feb;89(2):115-24
pubmed: 20090427
Pain Med. 2012 Oct;13(10):1366-76
pubmed: 22958298
Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S154-62
pubmed: 16273800
Int J Clin Pharmacol Res. 1998;18(1):13-9
pubmed: 9604730
Pain Res Manag. 2007 Spring;12(1):39-47
pubmed: 17372633
J Rheumatol. 1991 May;18(5):728-33
pubmed: 1865419
Am J Med. 1992 Apr;92(4):363-7
pubmed: 1558082
Rheum Dis Clin North Am. 2009 May;35(2):329-37
pubmed: 19647146
Pain Med. 2007 Jan-Feb;8(1):8-16
pubmed: 17244099
Pain Physician. 2012 Jul;15(3 Suppl):ES9-38
pubmed: 22786464
Pain. 2012 Dec;153(12):2332-8
pubmed: 22959600
JAMA. 2004 Nov 17;292(19):2388-95
pubmed: 15547167
BMC Musculoskelet Disord. 2007 Mar 09;8:27
pubmed: 17349056
Mayo Clin Proc. 2011 Sep;86(9):907-11
pubmed: 21878603
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Clin J Pain. 2015 Jan;31(1):7-13
pubmed: 24480913
Eur J Pain. 2010 Jan;14(1):5-10
pubmed: 19264521
Pain. 2001 Mar;91(1-2):165-75
pubmed: 11240089
Am J Med. 2003 May;114(7):537-45
pubmed: 12753877
J Rheumatol. 2013 Aug;40(8):1388-93
pubmed: 23818709
Qual Health Care. 1994 Dec;3(4):180-5
pubmed: 10140231
Pain Med. 2007 Nov-Dec;8(8):624-32
pubmed: 18028040